<DOC>
	<DOCNO>NCT02392312</DOCNO>
	<brief_summary>A multicenter , prospective , observational study evaluate safety efficacy individual batch ATG-F kidney transplant recipient .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Efficacy ATG-F Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<criteria>ATGF administration prophylaxis rejection kidney transplantation recipient . Patients capable understand purpose risk study , willing able participate study write date informed consent participate study obtain . Hypersensitivity active substance excipients. ) . Subjects bacterial , viral , mycotic parasitic infection , adequate therapeutic control . Solid organ transplant subject severe thrombocytopenia , i.e . le 50,000 platelets/Âµl ATGF may enhance thrombocytopenia thus increase risk hemorrhage . Current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin carcinoma insitu cervix treat successfully . Subject receive Human Leukocyte Antibody ( HLA ) identical living donor organ . Subject unlikely comply visit schedule protocol opinion investigator history noncompliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>ATG-F</keyword>
</DOC>